Evercore ISI raises UnitedHealth stock price target to $400 By Investing.com

Evercore ISI raised its UnitedHealth price target to $400 from $350 and reiterated Outperform, implying about 19x 2027 EPS. The firm said the latest quarter supports its turnaround thesis, with 2026 seen as a transition year and meaningful improvement likely in 2027-2028, especially at Optum. UnitedHealth also reported Q1 2026 adjusted EPS of $7.23 versus $6.59 expected and revenue of $111.7 billion versus $109.44 billion, while boosting 2026 EPS guidance to $18.25 from $17.75.

Analysis

UNH is looking less like a single-quarter earnings rebound and more like a multi-year repricing of execution risk. The important second-order effect is that pricing discipline in Medicare Advantage should improve near-term earnings quality while forcing weaker peers to choose between margin and membership — a setup that can widen dispersion across managed care into 2026. If the company can hold pricing without meaningful retention damage, the market will likely start to discount 2027–2028 normalization well before the fundamentals are fully visible.

The bigger implication is for the Optum complex: this is where the turnaround either compounds or stalls. A credible path to recovery there matters not just for UNH equity value, but for sentiment across healthcare services names that trade as if growth is secular even when reimbursement and utilization are cyclical. The stock’s rerating can continue even if the operational recovery is slow, because buybacks plus guidance resets create a floor under EPS while investors wait for evidence.

The main risk is that the market is underestimating the duration of remediation. If medical cost trends re-accelerate or pricing actions trigger membership leakage, this becomes a classic value trap: earnings can look fine for a few quarters while the forward multiple compresses on lower trust. The consensus seems to be pricing in a clean glide path; the more likely path is choppy execution with multiple reset points over the next 6–12 months.

For tactically oriented investors, the setup favors owning UNH versus other managed care names with weaker pricing power, but not chasing the move outright. The better trade is to express confidence in recovery through time decay and defined risk, because the core debate is not direction, it is the pace of normalization and how much of 2027 is already being pulled forward by the current rally.

Key Decisions for Investors

• Long UNH / short a basket of weaker managed care peers for 6–12 months; the relative trade benefits if UNH’s pricing actions prove sticky while peers absorb margin pressure.
• Buy UNH Jan-2027 or Jan-2028 call spreads on pullbacks; the thesis is multi-year, so structure the trade to capture rerating while limiting downside if turnaround timing slips.
• Avoid shorting UNH on the headline strength; instead wait for any post-earnings volatility to fade and use dips below the recent range to add, since buybacks and guidance support should cap drawdowns.
• If you want a contrarian hedge, short the most expensive healthcare services names with the weakest visibility into reimbursement normalization; the risk/reward improves if the market rotates toward earnings-quality over growth narratives.